BMC Infectious Diseases (Mar 2018)

Lymphnode tuberculosis in a 4-year-old boy with relapsed ganglioneuroblastoma: a case report

  • Karoline van de Loo,
  • Stefan Balzer,
  • Colin R. MacKenzie,
  • Thomas M. Boemers,
  • Monika Ortmann,
  • Jörg Schaper,
  • Arndt Borkhardt,
  • Hans-Jürgen Laws,
  • Michaela Kuhlen

DOI
https://doi.org/10.1186/s12879-018-3016-x
Journal volume & issue
Vol. 18, no. 1
pp. 1 – 4

Abstract

Read online

Abstract Background Mycobacterium tuberculosis (M. tuberculosis) disease is a generally well-known problem among immunocompromised adults and children. In pediatric oncology, only few cases of M. tuberculosis disease are reported so far. Case presentation We report a case of concomitant lymphnode tuberculosis in a 4-year-old German boy with relapsed ganglioneuroblastoma. 18 months after the initial diagnosis, relapse with new paravertebral lesions and new lesions in the left lower lobe of the lung and in the perihilar lymphnodes suspicious of metastases of the ganglioneuroblastoma were detected. While relapse in the tumor was confirmed, unexpectedly, pathologic examination revealed morphological diagnosis of lymphnode tuberculosis. The boy was of German background without previous history of tuberculosis exposure. Both, antituberculostatic and relapse treatment were immediately initiated. Three months on, MRI revealed regressive findings in the lung and lymphnodes and partial response in the tumor. The patient underwent second MiBG therapy and haploidentical stem cell transplantation. Conclusion The diagnosis of lymphnode tuberculosis in a 4-year-old German boy with relapsed ganglioneuroblastoma was only made by chance, but most likely saved his life. Pediatric oncologist should be aware of tuberculosis as the incidence might increase over time and the timely diagnosis of a potentially preventable M. tuberculosis disease is irreplaceable. Further studies are needed to explore the incidence of M. tuberculosis infections and the value of IGRA, testing for latent tuberculosis infection prior to chemotherapy in children with underlying malignancies.

Keywords